Apheresis Equipment Market - Global Forecast 2025-2032

The apheresis equipment market is entering a period of sustained transformation, driven by technology integration, increased clinical adoption, and evolving regulatory considerations. Senior leaders must navigate digitalization, operational resilience, and shifting healthcare priorities to capture future growth opportunities in this sector.

Market Snapshot: Growth and Competitive Landscape in Apheresis Equipment Market

The Apheresis Equipment Market grew from USD 3.15 billion in 2024 to USD 3.45 billion in 2025. It is expected to continue growing at a CAGR of 9.34%, reaching USD 6.45 billion by 2032. The sector is characterized by a diverse set of participants, including global device manufacturers, service providers, and clinical innovators, each responding to rapid shifts in automation, patient care trends, and global supply chain dynamics. Companies are increasingly leveraging targeted R&D investment and cross-sector alliances to expand product portfolios and reinforce customer engagement.

Scope & Segmentation of the Apheresis Equipment Market

• Product Types: Apheresis kits and accessories, cell separator systems, pathogen inactivation systems, plasma separation systems
• Applications: CAR T cell collection, stem cell collection, single donor plasma, source plasma, research use, therapeutic apheresis
• End Users: Blood centers, clinics, general hospitals, specialty hospitals, academic institutes, commercial research institutes
• Technology Platforms: Full automation centrifugal systems, semi-automation centrifugal systems, batch membrane systems, continuous flow membrane systems
• Patient Demographics: Adult, pediatric
• Regional Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland), Middle East (UAE, Saudi Arabia, Qatar, Turkey, Israel), Africa (South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
• Leading Innovators: Terumo Blood and Cell Technologies, Haemonetics, Fresenius Kabi, Macopharma, B. Braun Melsungen, Miltenyi Biotec, Grifols, Asahi Kasei Medical, Cerus Corporation, Fenwal

Key Takeaways for Decision-Makers

• Paradigm shifts in apheresis technology are expanding its clinical relevance from blood donation to cell therapy, immunotherapy, and precision medicine.
• Automation, digital integration, and single-use disposables are enhancing safety, procedure efficiency, and real-time monitoring while supporting remote and predictive analytics capabilities.
• Strategic investments in modular and scalable system architecture allow device manufacturers to align with diverse regulatory and clinical requirements, supporting long-term portfolio resilience.
• Growth in cell therapy applications and rising chronic disease prevalence drive demand for innovative collection and processing platforms among research institutes, clinics, and hospitals.
• Environmental sustainability is becoming central to procurement, with an emphasis on greener materials and energy-efficient designs throughout the device lifecycle.
• Strategic partnerships, digital service bundles, and emerging subscription-based models are increasing market accessibility and recurring revenue potential without increasing initial capital barriers.

Impact of United States Tariff Adjustments

With tariff reclassifications scheduled, operational costs and supply chain security are central concerns for device manufacturers and healthcare providers importing into the U.S. Stakeholders are increasingly exploring dual sourcing, nearshoring, and renegotiation of service contracts to mitigate exposure. Inventory and reimbursement models are also under review as part of a broader strategy for fiscal discipline and risk management.

Methodology & Data Sources

The findings in this report are based on comprehensive secondary research, supported by proprietary industry databases and patent analyses. Extensive primary interviews with executives, clinical practitioners, and regulatory specialists provided validation and context. Triangulation and scenario analysis ensured accurate segmentation and actionable insights into sector developments.

Why This Report Matters

• It empowers senior decision-makers to address rapid regulatory, technology, and clinical shifts with confidence and agility.
• It offers segment-level clarity, helping organizations refine market entry, product development, and investment strategies across regions and customer categories.
• Stakeholders can align operational frameworks, compliance structures, and digital transformation roadmaps to maximize both market and clinical value.

Conclusion

This analysis provides a strategic foundation for leadership teams aiming to strengthen positioning in the dynamic apheresis equipment landscape. By leveraging the actionable insights provided, stakeholders can drive innovation and long-term value in a rapidly evolving marketplace.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.